Report five-year Phase 2b melanoma data for intismeran autogene
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Jan 2026
- Due
- 30 Jun 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“look forward to the five-year Phase 2b melanoma data in early 2026 and the Phase 3 data, potentially in 2026.”
What we found
Evidence strength A What the grades mean
The 10-K filed 2026-02-20 states that five-year Phase 2b melanoma data were announced in January 2026, before the June 2026 deadline; the exact day is not given.
-
A Moderna 10-K filed 2026-02-20
“In January 2026, we and Merck announced five-year data from the Phase 2b study of intismeran autogene (mRNA-4157)” ✓ confirmed on the page
-
A Moderna 10-K filed 2026-02-20
“In January 2026, we and Merck announced five-year data from the Phase 2b study of intismeran in combination with KEYTRUDA” ✓ confirmed on the page
Market reaction: the shares moved +1.2% against the S&P 500 over the three sessions around the disclosure (19 Feb 2026 to 24 Feb 2026). What this measures
Checked 11 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +184 days
- 3 versions
-
Version 1 · original · stated 5 Jan 2026
Deadline 30 Jun 2026 (“in early 2026”)
-
Version 2 · stated 12 Jan 2026
Deadline 31 Mar 2026 (“in early 2026”) · wording expected
“In adjuvant melanoma, Moderna expects the five-year Phase 2b data in early 2026”
-
Version 3 · stated 13 Feb 2026
Deadline 31 Dec 2026 (“potentially in 2026”) · wording expected
“Moderna expects Phase 3 adjuvant melanoma data potentially in 2026.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Five-year Phase 2b melanoma data for intismeran autogene
- In the company’s control
- Medium
- Specificity
- Low
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-MRNA-006251 · Corrections policy